Document is current
Any future updates will be listed below
-
Authors
Forster, Stefan
Reinhardt, Chantal
Boy, Maxime
Wegmüller, Adrian https://orcid.org/0009-0003-1203-2990
Hinrichsen, Alessio
Schürch, Christian M. https://orcid.org/0000-0002-1792-1768
Brühl, Frido K. https://orcid.org/0000-0001-6409-0824
Fend, Falko https://orcid.org/0000-0002-5496-293X
Tzankov, Alexandar
Kronig, Marie-Noëlle
Römmele, Michaela
Glück, Angéline https://orcid.org/0009-0005-5883-6120
Lüscher, Benjamin
Legros, Myriam
Bacher, Ulrike
Seipel, Katja
Pabst, Thomas https://orcid.org/0000-0002-6055-5257
Radpour, Ramin https://orcid.org/0000-0002-5632-7833
Riether, Carsten https://orcid.org/0000-0001-7512-513X
Ochsenbein, Adrian F. https://orcid.org/0000-0003-1773-5436
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030-236111)
- License Information
-
More Information
Article History
Received: 12 August 2025
Revised: 19 January 2026
Accepted: 24 February 2026
First Online: 23 March 2026
Competing interests
: AFO, CR and CMS are listed inventors on United States Patents No. US 10,391,168 B1 and US 11,571,475 B1 related to anti-CD70 therapy in leukemia, assigned to the University of Bern. AFO and CR are listed on the Patents No. US20200222532A1 and GB1709677.7A.
: All methods were carried out in accordance with relevant guidelines and regulations and the Declaration of Helsinki. This study was approved by the Ethics Committee, University of Tübingen (approvals 522/2015BO2 and 462/2022BO2) and the local ethical committee of the Canton of Bern, Switzerland (approval 2019-01627). Written informed consent was obtained from all participants prior to inclusion in the study. Animal experiments were approved by the local animal committee of the Canton of Bern and performed according to the Swiss laws for animal protection (BE12/21).
